{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:49:25Z","timestamp":1790650165087,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Camurus AB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40262-023-01288-6","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T09:01:47Z","timestamp":1692176507000},"page":"1427-1443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder"],"prefix":"10.1007","volume":"62","clinical-trial-number":[{"clinical-trial-number":"isrctn41550730","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn24987553","registry":"10.18810\/isrctn"},{"clinical-trial-number":"nct02710526","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Marcus","family":"Bj\u00f6rnsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayan","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Strandg\u00e5rden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Tiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"1288_CR1","unstructured":"Dydyk AM, Jain NK, Gupta M. Opioid use disorder. Statpearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2022, StatPearls Publishing LLC.; 2022."},{"issue":"1","key":"1288_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1172\/JCI134708","volume":"130","author":"ND Volkow","year":"2020","unstructured":"Volkow ND, Blanco C. Medications for opioid use disorders: Clinical and pharmacological considerations. J Clin Invest. 2020;130(1):10\u20133. https:\/\/doi.org\/10.1172\/JCI134708.","journal-title":"J Clin Invest"},{"key":"1288_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Substance-related and addictive disorders. Diagnostic and statistical manual of mental disorders: Dsm-5-tr. 5th Edition, Text","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. Substance-related and addictive disorders. Diagnostic and statistical manual of mental disorders: Dsm-5-tr. 5th Edition, Text. Revision. Washington, DC: American Psychiatric Association; 2022. p. 543\u2013665.","edition":"Revision"},{"issue":"5","key":"1288_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9041","volume":"4","author":"N Lintzeris","year":"2021","unstructured":"Lintzeris N, Dunlop AJ, Haber PS, Lubman DI, Graham R, Hutchinson S, Arunogiri S, Hayes V, Hjelmstr\u00f6m P, Svedberg A, Peterson S, Tiberg F. Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial. JAMA Netw. 2021;4(5): e219041. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.9041.","journal-title":"JAMA Netw"},{"issue":"4","key":"1288_CR5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40262-020-00957-0","volume":"60","author":"AK Jones","year":"2021","unstructured":"Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM. Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: a combined analysis of Phase ii and Phase iii trials. Clin Pharmacokinet. 2021;60(4):527\u201340. https:\/\/doi.org\/10.1007\/s40262-020-00957-0.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1288_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/adm.0000000000000457","volume":"13","author":"MA Coe","year":"2019","unstructured":"Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: Update on transmucosal and long-acting formulations. J Addict Med. 2019;13(2):93\u2013103. https:\/\/doi.org\/10.1097\/adm.0000000000000457.","journal-title":"J Addict Med"},{"issue":"5","key":"1288_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/adm.0000000000000045","volume":"8","author":"MR Lofwall","year":"2014","unstructured":"Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8(5):315\u201326. https:\/\/doi.org\/10.1097\/adm.0000000000000045.","journal-title":"J Addict Med"},{"issue":"3","key":"1288_CR8","doi-asserted-by":"publisher","first-page":"37517","DOI":"10.52965\/001c.37517","volume":"10","author":"S Poliwoda","year":"2022","unstructured":"Poliwoda S, Noor N, Jenkins JS, Stark CW, Steib M, Hasoon J, Varrassi G, Urits I, Viswanath O, Kaye AM, Kaye AD. Buprenorphine and its formulations: a comprehensive review. Health Psychol Res. 2022;10(3):37517. https:\/\/doi.org\/10.52965\/001c.37517.","journal-title":"Health Psychol Res"},{"key":"1288_CR48","unstructured":"Food and Drug Administration (FDA) BRIXADI\u2122 prescribing information 2023;51782898."},{"key":"1288_CR49","unstructured":"European Medicines Agency (EMA). Buvidal: EPAR - Risk-management-plan summary. 2021;EMEA\/H\/C\/004621."},{"issue":"9","key":"1288_CR9","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","volume":"74","author":"SL Walsh","year":"2017","unstructured":"Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, Coe MA, Jones JD, Nuzzo PA, Tiberg F, Sheldon B, Kim S. Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiat. 2017;74(9):894\u2013902. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1874.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"1288_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","volume":"178","author":"MR Lofwall","year":"2018","unstructured":"Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, Oosman S, Peterson S, Chen M, Kim S. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178(6):764\u201373. https:\/\/doi.org\/10.1001\/jamainternmed.2018.1052.","journal-title":"JAMA Intern Med"},{"issue":"8","key":"1288_CR11","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/add.14636","volume":"114","author":"M Frost","year":"2019","unstructured":"Frost M, Bailey GL, Lintzeris N, Strang J, Dunlop A, Nunes EV, Jansen JB, Frey LC, Weber B, Haber P, Oosman S, Kim S, Tiberg F. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction. 2019;114(8):1416\u201326. https:\/\/doi.org\/10.1111\/add.14636.","journal-title":"Addiction"},{"key":"1288_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-1-4614-0554-2_16","volume-title":"Long-acting injections and implants","author":"F Tiberg","year":"2012","unstructured":"Tiberg F, Johnsson M, Nistor C, Joabsson F. Self-assembling lipid formulations. In: Wright J, Burgess D, editors. Long-acting injections and implants. New York: Springer Science & Business Media; 2012. p. 315\u201334."},{"issue":"2","key":"1288_CR13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","volume":"34","author":"M Albayaty","year":"2017","unstructured":"Albayaty M, Linden M, Olsson H, Johnsson M, Strandg\u00e5rden K, Tiberg F. Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: An open-label Phase 1 study. Adv Ther. 2017;34(2):560\u201375. https:\/\/doi.org\/10.1007\/s12325-016-0472-9.","journal-title":"Adv Ther"},{"issue":"3","key":"1288_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.drugalcdep.2012.11.014","volume":"131","author":"MA Huestis","year":"2013","unstructured":"Huestis MA, Cone EJ, Pirnay SO, Umbricht A, Preston KL. Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. Drug Alcohol Depen. 2013;131(3):258\u201362. https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.11.014.","journal-title":"Drug Alcohol Depen"},{"issue":"3","key":"1288_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.taap.2005.08.002","volume":"212","author":"B M\u00e9garbane","year":"2006","unstructured":"M\u00e9garbane B, Marie N, Pirnay S, Borron S, Gueye P, Ris\u00e8de P, Monier C, Noble F, Baud F. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharm. 2006;212(3):256\u201367. https:\/\/doi.org\/10.1016\/j.taap.2005.08.002.","journal-title":"Toxicol Appl Pharm"},{"issue":"18","key":"1288_CR16","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1080\/14656566.2017.1409722","volume":"18","author":"M Dematteis","year":"2017","unstructured":"Dematteis M, Auriacombe M, D\u2019Agnone O, Somaini L, Szerman N, Littlewood R, Alam F, Alho H, Benyamina A, Bobes J, Daulouede JP, Leonardi C, Maremmani I, Torrens M, Walcher S, Soyka M. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmaco. 2017;18(18):1987\u201399. https:\/\/doi.org\/10.1080\/14656566.2017.1409722.","journal-title":"Expert Opin Pharmaco"},{"issue":"10173","key":"1288_CR17","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","volume":"393","author":"BR Haight","year":"2019","unstructured":"Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbreder C, Andersen JL, Bailey GL, Bartley SR, Biunno MJ, Boyett B, Carr JM, Cifuentes E, Duarte-Sckell SD, Dueno OR, Harrison BJ, Hassman DR, Hoffman KS, Isacesu V, Ishaque S, Kakar R, Kampman K, Knapp RD, Konis G, Kunovac J, Kwentus JA, Levinson LS, Malhotra S, Mehra V, Mofsen RS, Peyton ML, Pujari GG, Ranjan R, Rutrick D, Seal G, Segal SD, Shiwach R, Thomas HM, Ventre PP, Vijapura AK, Walling DP, Wiest KL. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2019;393(10173):778\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(18)32259-1.","journal-title":"Lancet"},{"issue":"7","key":"1288_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/jcph.665","volume":"56","author":"CM Laffont","year":"2016","unstructured":"Laffont CM, Gomeni R, Heidbreder C, Jones J III, Nasser AF. Population pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder. J Clin Pharmacol. 2016;56(7):806\u201315. https:\/\/doi.org\/10.1002\/jcph.665.","journal-title":"J Clin Pharmacol"},{"key":"1288_CR19","volume-title":"Nonmem user\u2019s guides (1989\u20132014)","author":"S Beal","year":"2014","unstructured":"Beal S, Sheiner L, Boeckmann A, Bauer R. NONMEM user\u2019s guides (1989\u20132014). Ellicott City: Icon Development Solutions; 2014."},{"issue":"3","key":"1288_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Meth Prog Biol. 2005;79(3):241\u201357. https:\/\/doi.org\/10.1016\/j.cmpb.2005.04.005.","journal-title":"Comput Meth Prog Biol"},{"issue":"2","key":"1288_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2014a perl module for NONMEM related programming. Comput Meth Prog Biol. 2004;75(2):85\u201394. https:\/\/doi.org\/10.1016\/j.cmpb.2003.11.003.","journal-title":"Comput Meth Prog Biol"},{"key":"1288_CR22","unstructured":"R Core Team. R: A language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. 2017; Available from: https:\/\/www.r-project.org\/."},{"issue":"1","key":"1288_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO. Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Meth Prog Bio. 1999;58(1):51\u201364. https:\/\/doi.org\/10.1016\/s0169-2607(98)00067-4.","journal-title":"Comput Meth Prog Bio."},{"issue":"9","key":"1288_CR24","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/a:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463\u20138. https:\/\/doi.org\/10.1023\/a:1011970125687.","journal-title":"Pharm Res"},{"issue":"2","key":"1288_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"key":"1288_CR26","unstructured":"Karlsson MO, Holford, N. A tutorial on visual predictive checks (abstract no. 1434). Population Approach Group in Europe (PAGE) 2008. [cited August 2023]. https:\/\/www.page-meeting.org\/?abstract=1434."},{"issue":"12","key":"1288_CR27","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00228-007-0377-2","volume":"63","author":"M Jensen","year":"2007","unstructured":"Jensen M, Foster D, Upton R, Kristensen K, Hansen S, Jensen N-H, Nielsen B, Skram U, Villesen HH, Christrup L. Population pharmacokinetics of buprenorphine following a two-stage intravenous infusion in healthy volunteers. Eur J Clin Pharmacol. 2007;63(12):1153\u20139. https:\/\/doi.org\/10.1007\/s00228-007-0377-2.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1288_CR28","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1097\/00000542-200606000-00019","volume":"104","author":"A Yassen","year":"2006","unstructured":"Yassen A, Olofsen E, Romberg R, Sarton E, Danhof M, Dahan A. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology. 2006;104(6):1232\u201342. https:\/\/doi.org\/10.1097\/00000542-200606000-00019.","journal-title":"Anesthesiology"},{"key":"1288_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.drugalcdep.2005.08.005","volume":"82","author":"P Compton","year":"2006","unstructured":"Compton P, Ling W, Moody D, Chiang N. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend. 2006;82:25\u201331. https:\/\/doi.org\/10.1016\/j.drugalcdep.2005.08.005.","journal-title":"Drug Alcohol Depend"},{"key":"1288_CR30","unstructured":"Walsh S, Comer S, Sarr C, Bj\u00f6rnsson M, Strandg\u00e5rden K, Hjelmstr\u00f6m P, Tiberg F. Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder. Neurophycopharmacol. (under review)."},{"issue":"1","key":"1288_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03639045.2019.1706552","volume":"46","author":"P Hjelmstr\u00f6m","year":"2020","unstructured":"Hjelmstr\u00f6m P, Banke Nordbeck E, Tiberg F. Optimal dose of buprenorphine in opioid use disorder treatment: A review of pharmacodynamic and efficacy data. Drug Dev Ind Pharm. 2020;46(1):1\u20137. https:\/\/doi.org\/10.1080\/03639045.2019.1706552.","journal-title":"Drug Dev Ind Pharm"},{"key":"1288_CR32","unstructured":"Food and Drug Administration (FDA). Suboxone\u00ae prescribing information 2010."},{"key":"1288_CR33","unstructured":"Food and Drug Administration (FDA). Subutex\u00ae highlights of prescribing information; 2011."},{"issue":"5","key":"1288_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1521-0391.2011.00153.x","volume":"20","author":"EW Gunderson","year":"2011","unstructured":"Gunderson EW, Levin FR, Rombone MM, Vosburg SK, Kleber HD. Improving temporal efficiency of outpatient buprenorphine induction. Am J Addict. 2011;20(5):397\u2013404. https:\/\/doi.org\/10.1111\/j.1521-0391.2011.00153.x.","journal-title":"Am J Addict"},{"issue":"7","key":"1288_CR35","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/ajad.12288","volume":"24","author":"P Jacobs","year":"2015","unstructured":"Jacobs P, Ang A, Hillhouse MP, Saxon AJ, Nielsen S, Wakim PG, Mai BE, Mooney LJ, Potter SJ, Blaine JD. Treatment outcomes in opioid dependent patients with different buprenorphine\/naloxone induction dosing patterns and trajectories. Am J Addict. 2015;24(7):667\u201375. https:\/\/doi.org\/10.1111\/ajad.12288.","journal-title":"Am J Addict"},{"issue":"1\u20132","key":"1288_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","volume":"128","author":"AJ Saxon","year":"2013","unstructured":"Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, Doraimani G, Tasissa G, Lokhnygina Y, Leimberger J, Bruce RD, McCarthy J, Wiest K, McLaughlin P, Bilangi R, Cohen A, Woody G, Jacobs P. Buprenorphine\/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depen. 2013;128(1\u20132):71\u20136. https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.08.002.","journal-title":"Drug Alcohol Depen"},{"issue":"10208","key":"1288_CR37","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/s0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, Larney S. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560\u201379. https:\/\/doi.org\/10.1016\/s0140-6736(19)32229-9.","journal-title":"Lancet"},{"issue":"4","key":"1288_CR38","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/pm\/pnz356","volume":"21","author":"L Webster","year":"2020","unstructured":"Webster L, Gudin J, Raffa RB, Kuchera J, Rauck R, Fudin J, Adler J, Mallick-Searle T. Understanding buprenorphine for use in chronic pain: Expert opinion. Pain Med. 2020;21(4):714\u201323. https:\/\/doi.org\/10.1093\/pm\/pnz356.","journal-title":"Pain Med"},{"key":"1288_CR39","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.2147\/jpr.S231948","volume":"12","author":"JV Pergolizzi Jr","year":"2019","unstructured":"Pergolizzi JV Jr, Raffa RB. Safety and efficacy of the unique opioid buprenorphine for the treatment of chronic pain. J Pain Res. 2019;12:3299\u2013317. https:\/\/doi.org\/10.2147\/jpr.S231948.","journal-title":"J Pain Res"},{"issue":"4","key":"1288_CR40","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.bja.2017.11.086","volume":"120","author":"LD White","year":"2018","unstructured":"White LD, Hodge A, Vlok R, Hurtado G, Eastern K, Melhuish TM. Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomised controlled trials. Br J Anaesth. 2018;120(4):668\u201378. https:\/\/doi.org\/10.1016\/j.bja.2017.11.086.","journal-title":"Br J Anaesth"},{"issue":"1","key":"1288_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40122-019-00143-6","volume":"9","author":"J Gudin","year":"2020","unstructured":"Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther. 2020;9(1):41\u201354. https:\/\/doi.org\/10.1007\/s40122-019-00143-6.","journal-title":"Pain Ther"},{"issue":"6","key":"1288_CR42","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/bja\/aei145","volume":"94","author":"A Dahan","year":"2005","unstructured":"Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94(6):825\u201334. https:\/\/doi.org\/10.1093\/bja\/aei145.","journal-title":"Br J Anaesth"},{"issue":"5","key":"1288_CR43","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/bja\/ael051","volume":"96","author":"A Dahan","year":"2006","unstructured":"Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627\u201332. https:\/\/doi.org\/10.1093\/bja\/ael051.","journal-title":"Br J Anaesth"},{"issue":"11","key":"1288_CR44","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1007\/s12325-020-01481-0","volume":"37","author":"LR Webster","year":"2020","unstructured":"Webster LR, Hansen E, Cater J, Smith T. A Phase I placebo-controlled trial comparing the effects of buprenorphine buccal film and oral oxycodone hydrochloride administration on respiratory drive. Adv Ther. 2020;37(11):4685\u201396. https:\/\/doi.org\/10.1007\/s12325-020-01481-0.","journal-title":"Adv Ther"},{"issue":"7","key":"1288_CR45","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5055\/jom.2021.0648","volume":"17","author":"L Webster","year":"2021","unstructured":"Webster L, Rauck RL. Atypical opioids and their effect on respiratory drive. J Opioid Manag. 2021;17(7):109\u201318. https:\/\/doi.org\/10.5055\/jom.2021.0648.","journal-title":"J Opioid Manag"},{"issue":"2","key":"1288_CR46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1124\/jpet.113.209478","volume":"348","author":"DA Tompkins","year":"2014","unstructured":"Tompkins DA, Smith MT, Mintzer MZ, Campbell CM, Strain EC. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. J Pharmacol Exp Ther. 2014;348(2):217\u201326. https:\/\/doi.org\/10.1124\/jpet.113.209478.","journal-title":"J Pharmacol Exp Ther"},{"key":"1288_CR47","unstructured":"United States Drug Enforcement Administration (DEA). Drug scheduling. 2018 [cited August 2023]. https:\/\/www.dea.gov\/drug-information\/drug-scheduling."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01288-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01288-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01288-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T08:29:16Z","timestamp":1695630556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01288-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1288"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01288-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]},"assertion":[{"value":"17 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis was sponsored by Camurus AB. Support for third-party writing assistance for this article, provided by Lucy-Paige Willows, BSc, and Rachel Hutchinson, PhD, Costello Medical, UK, was funded by Camurus AB in accordance with Good Publication Practice (GPP3) guidelines ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MB: Current employee and stock owner of Pharmetheus AB. CA: Current employee of Pharmetheus AB. KS: Employee of Camurus AB at the time of the analysis. Currently a consultant in Pharmacokinetics and Pharmacometrics at PKadvisor AB. FT: Current employee and shareholder of Camurus AB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The authors will not make data collected for the study analysis available to others.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Ethics approval and informed consent of each trial participant were obtained before trial inclusion, as detailed previously in the primary publications from the 4 clinical trials or within the appropriate records on the ISRCTN.com or ClinicalTrials.gov registries (registration numbers: ISRCTN41550730, ISRCTN24987553, NCT02611752 and NCT02710526). These 4 clinical trials, and the analysis detailed here, were conducted in accordance with Good Clinical Practice Guidelines and the ethical principles as laid down in the 1964 Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Oral and written informed consent to participate was obtained from all trial participants before enrollment in the trials.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All the results presented in this article are in aggregate form, and no personally-identifiable information was used for this analysis.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Due to its proprietary nature, the authors will not make code available to others.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Substantial contributions to analysis conception and design: MB, CA, KS, and FT; substantial contributions to analysis and interpretation of the data: MB, CA, KS, and FT; drafting the article or revising it critically for important intellectual content: MB, CA, KS, and FT; final approval of the version of the article to be published: MB, CA, KS, and FT.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}